Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

(2018) Michael Hallek et al.   BLOOD

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

(2018) Ajai Chari et al.   CANCER

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

(2015) P. A. Thompson et al.   BLOOD

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

(2015) K. Fischer et al.   BLOOD

Update on rupatadine in the management of allergic disorders

(2014) J. Mullol et al.   ALLERGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

(2012) Roger G. Owen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy

(2008) C. H. Chung   ONCOLOGIST

Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study

(2008) Lee S. Schwartzberg et al.   SUPPORTIVE CARE IN CANCER